Based in Melbourne, Australia, Patrys is a publicly-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development.